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of the biologic agents currently utilized in the United States for
this indication (adalimumab, alefacept, efalizumab, etanercept
and inﬂiximab). Model results were displayed for a time horizon
of one year based on a switch to an appropriate alternate biologic
agent in the event of suboptimal clinical response. Multiple one-
way sensitivity analyses were conducted. RESULTS: Across all
the biologics evaluated there are signiﬁcant differences in PASI 75
response at 12 weeks versus longer term (ranging from 59% to
20% across the agents at the end of one quarter of treatment and
at the end of four quarters of treatment, respectively). The cost
per PASI 75 was observed to be $26,460, $31,191, $28,217,
$30,544 and $30,983 for therapy initiated with adalimumab,
alefacept, efalizumab, etanercept and inﬂiximab, respectively.
CONCLUSION: While there are signiﬁcant differences in the
cost of the studied biologic agents initially, the CE results tend to
converge over the ﬁrst year of treatment. Further research needs
to be conducted to evaluate the CE of treatment beyond a one-
year period.
PSS19
A PHARMACOECONOMIC EVALUATION OF PEGAPTANIB
FORTHE MANAGEMENT OF AGE-RELATED MACULAR
DEGENERATION (AMD) IN MEXICO
Vega-Hernández GY1, Idrovo-Velandia J2, Rivas R3, Zapata L3,
Venegas J4, Ramírez H5, Mould-Quevedo J6, Davila-Loaiza G6
1Pﬁzer Mexico, DF, Mexico City, Mexico, 2Insituto Nacional de Salud
Pública, Cuernavaca, Morelos, Morelos, Mexico, 3Guia Mark, México,
DF, Mexico, 4Guiamark SC, Mexico City, Mexico, 5Guiamark SC,
Mexico City, Mexico City, Mexico, 6Pﬁzer Mexico, Mexico City, Mexico
OBJECTIVE: In western countries AMD is considered one of the
most important causes of blindness among persons over 65 years
old. The purpose of this study was to determine the cost-
effectiveness of pegaptanib vs verteporﬁn in the treatment of
AMD from the health care payer’s perspective. METHODS: A
seven-stage stochastic Markov model based on visual acuity (VA)
in the better seeing-eye (stages: with clinical beneﬁt, VA>20/40;
VA:20/40–20/; VA:20/100–20/160; VA:20/200–20/500; VA < 20/
500 and legal blindness) was performed during a ﬁve-year
period. Effectiveness measure used in the assessment was the
probability to gain at least one-level of VA at the end of the
follow up period. Effectiveness data was obtained from interna-
tional published literature. Comparators used in the model were
pegaptanib 0.3 mg (8 sessions) and verteporﬁn 15 mg (10 ses-
sions). Resource use and cost data were obtained from hospital
records and ofﬁcial institutional databases from the Social Secu-
rity Mexican Institute (IMSS). Costs and health outcomes were
discounted with a 3% annual rate. The model was calibrated.
Probabilistic sensitivity analyses were performed to determine
the results robustness. RESULTS: Patients who received pegap-
tanib experienced a higher probability to gain at least one level of
VA(57.4%; CI95%:52.26%–62.54%) compared with patients
treated with verteporﬁn (13.8%; IC95%:10.61%–16.99%) con-
sidering an initial VA state of “>20/40”(p < 0.001). Mean total
costs per patient were higher in patients who received pegaptanib
compared to those who received verteporﬁn (US$6749;
CI95%:US$6401–US$7096 vs. US$6311 CI95%:US$5948–
US$6674; respectively). The ICER in patients receiving pegap-
tanib compared to those receiving verteporﬁn was US$1004
(CI95% US$926–US$1090). Sensitivity analyses found that
pegaptanib is a cost-saving strategy when the numbers of sessions
given to the patients are less than three. CONCLUSION: The
results show that in Mexico, pegaptanib is a cost-effective
therapy for AMD when is compared with verteporﬁn. These
results should be taken into account by Mexican decision makers
in the management of patients with AMD.
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OBJECTIVE: Blepharokeratoconjunctivitis (BKC) is a disease
characterized by inﬂammation of the eye lid, conjunctiva and
cornea and is typically treated empirically with topical antibiotic/
anti-inﬂammatory agents. The purpose of this study was to
compare the cost-effectiveness of tobramycin 0.3%/loteprednol
0.5%, (Zylet) to tobramycin 0.3%/dexamethasone 0.1%, (Tobra-
dex) for the rapid control of BKC. METHODS: Effectiveness
data for this analysis came from a randomized, double-masked,
parallel-group study of forty patients with BKC. Patients were
treatedwith eitherZylet™orTobradex®administered twice daily
in the test eye. Themeasure of effectiveness usedwas the change in
a clinical composite score of four BKC components: blepharitis,
ocular discharge, conjunctivitis, and corneal punctuate epithelial
keratopathy (PEK). Each clinical component was graded on a
scale of 0 (minimum) to three (extensive) and assessed at baseline
and on day 4 (1) of therapy. Five different pharmacy chains were
surveyed as to their prices for a 5ml bottle of both Tobradex and
Zylet. The average price of each agent was used as the cost
measure in the analysis. A probabilistic sensitivity analysis evalu-
ated the robustness of the economic outcomes. The economic
perspective was that of the payer. Due to the short time span
no cost discounting was performed. RESULTS: Reductions in
the BKC clinical composite scores at the day-4 assessment were
calculated at 4.5 (SD  1.7) versus 7.1 (SD  1.2) for the Zylet
and Tobradex groups, respectively. The average retail costs for
Zylet and Tobradex were $96.45 (SD  $5.26) and $71.75
(SD  $5.48) respectively. The cost-effectiveness ratios for Zylet
and Tobradex therapy were $21.43 and $10.10, respectively. The
cost-effectiveness results remained consistent using the probabi-
listic sensitivity distributions tested. CONCLUSION: Tobradex
economically dominated Zylet for the rapid control of BKC
because it was both less costly and more effective.
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OBJECTIVE: InGermany, 26%of reported and 36% (= 8’460) of
conﬁrmed work-related diseases are skin-related, in over 90% of
these cases hands are affected. However, there is a lack on com-
prehensive information on costs associated with chronic hand
eczema (CHE). The objective of this study was to assess the direct
and indirect costs of CHE.METHODS:Data on 151 Patientswith
occupational skin diseases entering a special rehabilitation
program were assessed for the preceding 12 months. Data were
derived from patient records and direct patient information.
Descriptive analyses froma societal perspectivewas performed for
all patients and by physician-rated severity (severity group 1:
no/mild; group 2: moderate/severe). DGUV (German Statutory
Accident Insurance) was the payer for all patients. RESULTS:
Mean age was 44.9 years, 64.9% of patients were male. Total
mean annual costs amounted to €8.160 (95% CI: 6.395–9.925)
per patient. Indirect costs represented 75% of total costs,
in-patient-rehabilitation 14%. Each other factor (out-patient ser-
vices, diagnostics, drugs, complementary therapies, out-of-pocket
expenses) contributed < 3% to overall costs. Disease severity
inﬂuencedQoL signiﬁcantly (DLQI-score of severity group 1: 7.9,
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